[Therapy of hormone refractory prostatic carcinoma].
In patients with hormone-resistant prostate cancer primary androgen deprivation eventually fails. The begin of secondary treatment is depending on clinical symptoms; since survival cannot be prolonged in progressive disease improvement of quality of life is of paramount importance. Altering of endocrine treatment and antiandrogen withdrawal can cause a transient improvement of the sense of well being. Single agent chemotherapy with little side effects should be preferred as compared with polychemotherapy since response rates do not exceed 30%. Although 2/3 of the patients benefit from chemotherapy there is however no proof that it is superior to symptom-related pain relief. The indication for surgical management such as TURP and spinal cord decompression is depending on clinical symptoms from local progression and systemic disease.